Is my portfolio
One Report to Answer all your Questions!
Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
902.15
10.60 (1.19%) Zydus Lifesciences submits press release
Date: 28-02-2026Zydus Lifesciences has submitted a press release stating that Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg.
The above information is a part of company’s filings submitted to BSE.